[144] Chemed Corporation SEC Filing

Rhea-AI Filing Summary

Chemed Corporation (CHE) notice of proposed sale reports an intended sale of 556 common shares with an aggregate market value of $232,410.94, representing holdings out of 14,571,695 shares outstanding. The approximate date of sale is 07/31/2025 and the transaction lists Merrill Lynch, 401 E Las Olas Blvd., Fort Lauderdale, FL as the broker and the NYSE as the exchange. The shares were acquired as stock awards: 262 shares on 05/16/2022 and 294 shares on 05/15/2023, with payment recorded on the acquisition dates. The filer indicates no securities sold in the past three months and includes the standard representation that they are unaware of undisclosed material adverse information about the issuer.

Positive

• Transparent disclosure of the intended sale including broker, exchange, and aggregate market value
• Acquisition details provided showing the shares were received as stock awards with dates and amounts

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider sale notice showing a small planned disposition of vested stock awards, with no recent sales reported.

The Form 144 discloses a proposed sale of 556 common shares valued at $232,410.94, executed through Merrill Lynch and scheduled for 07/31/2025. The holdings derive from two stock awards vested in 2022 and 2023. There are no reported sales in the prior three months, indicating this filing documents a planned, rather than recurring, disposition. For investors, this appears procedural and consistent with normal post-vesting sales by insiders, with no additional operational or financial data disclosed.

Corporate Governance Expert

TL;DR: Compliance-focused filing that meets disclosure requirements under Rule 144; contains standard attestations.

The notice includes the required acquisition details, broker information, and a signer representation regarding material undisclosed information, satisfying Rule 144 procedural disclosures. The acquisition types are listed as stock awards with payment dates matching grant/vesting dates. The absence of prior three-month sales simplifies aggregation considerations. From a governance perspective, the filing reflects routine insider transparency without revealing governance or control changes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	Merrill Lynch 401 E Las Olas Blvd., FLR 9 Fort Lauderdale FL 33301	556	232410.94	14571695	07/31/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	05/16/2022	stock award	N/A			262	05/16/2022	n/a
common	05/15/2023	stock award	n/a			294	05/15/2023	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Chemed Corporation's Form 144 filed for CHE disclose?

The filing discloses a proposed sale of 556 common shares valued at $232,410.94, to be executed on or about 07/31/2025 through Merrill Lynch on the NYSE.

How were the shares being sold by CHE acquired?

The shares were acquired as stock awards: 262 shares on 05/16/2022 and 294 shares on 05/15/2023, with payment recorded on the acquisition dates.

Did the filer report any Chemed (CHE) sales in the past three months?

No. The Form 144 lists Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

What broker and exchange are named in the CHE Form 144?

The broker listed is Merrill Lynch, 401 E Las Olas Blvd., Fort Lauderdale, FL, and the exchange named is the NYSE.

Does the filing include any statement about undisclosed material information?

Yes. The signer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.